Recently, TDO2 has been verified to strongly expressed in various cancers, including glioma, breast cancer, lung cancer, esophageal squamous cell carcinoma (ESCC), and could affect cancer biological features, including proliferation and metastasis, directly (9, 10, 34–36). Here, TDO2 is linked to glioma.